
Quidel Corporation Net Debt 2011-2026 | QDEL
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Quidel Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -377 M | 59.5 M | 63.9 M | 361 M | -21.1 M | -43.6 M | -53.7 M | -2.82 M | -3.91 M | -13.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 361 M | -377 M | -2.99 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
-6.88 M | $ 13.71 | -0.22 % | $ 99.4 M | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
231 M | $ 8.62 | 0.23 % | $ 574 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 155.46 | 1.83 % | $ 7.71 B | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 25.56 | 0.95 % | $ 710 M | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 17.01 | 3.4 % | $ 906 M | ||
|
DexCom
DXCM
|
-842 M | $ 64.24 | -1.56 % | $ 25.1 B | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | $ 103.57 | 0.29 % | $ 19.5 B | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 14.77 | 0.61 % | $ 447 M | ||
|
Guardant Health
GH
|
1.15 B | $ 85.49 | 1.75 % | $ 10.7 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
14.5 M | $ 17.88 | -6.63 % | $ 2.32 B | ||
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 2.83 | -1.05 % | $ 91.8 K | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 98.33 | 0.9 % | $ 8.11 B | ||
|
Danaher Corporation
DHR
|
14 B | $ 187.32 | 0.57 % | $ 134 B | ||
|
IQVIA Holdings
IQV
|
12 B | $ 164.72 | 1.1 % | $ 28.3 B | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
-494 M | $ 118.94 | 2.92 % | $ 18.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 199.7 | -0.46 % | $ 22.2 B | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
1.24 B | $ 111.51 | -0.06 % | $ 33.9 B | ||
|
BioNano Genomics
BNGO
|
-2.64 M | $ 1.11 | -0.89 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
-12.1 M | $ 9.0 | -0.99 % | $ 255 M | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 173.74 | 0.49 % | $ 24.2 B | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Neogen Corporation
NEOG
|
751 M | $ 9.09 | -2.78 % | $ 1.97 B | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
-11.9 M | - | - | $ 79.8 M | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 450.41 | 1.48 % | $ 13 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 16.52 | 0.12 % | $ 370 M | ||
|
Celcuity
CELC
|
82.8 M | $ 114.22 | 3.11 % | $ 4.51 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
NeoGenomics
NEO
|
187 M | $ 7.88 | -1.25 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
OPKO Health
OPK
|
-411 M | $ 1.19 | 2.59 % | $ 826 M | ||
|
Natera
NTRA
|
-177 M | $ 187.85 | -1.29 % | $ 18.5 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.66 | -3.92 % | $ 432 M | ||
|
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.33 | 4.72 % | $ 399 M |